Financial Ratios Shanghai Shyndec Pharmaceutical Co., Ltd.
Equities
600420
CNE000001JG2
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.610 CNY | -0.31% |
|
+0.21% | -4.85% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.61 | 2.72 | 3.1 | 4.94 | 3.55 | |||||
Return on Total Capital | 4.78 | 3.49 | 3.9 | 6.08 | 4.3 | |||||
Return On Equity % | 8.13 | 7.7 | 7.28 | 8.98 | 7.33 | |||||
Return on Common Equity | 6.8 | 6.64 | 6.1 | 8.47 | 6.98 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 43.28 | 37.57 | 37.55 | 37.63 | 31.24 | |||||
SG&A Margin | 30.26 | 26.35 | 24.07 | 17.56 | 13.67 | |||||
EBITDA Margin % | 13.28 | 12.85 | 14.63 | 21.07 | 19.36 | |||||
EBITA Margin % | 7.94 | 6.74 | 8.27 | 14.54 | 12.54 | |||||
EBIT Margin % | 7.73 | 6.49 | 8.01 | 14.19 | 11.9 | |||||
Income From Continuing Operations Margin % | 5.89 | 6.69 | 7.99 | 12.18 | 12.2 | |||||
Net Income Margin % | 4.08 | 4.84 | 5.73 | 9.91 | 10.06 | |||||
Net Avail. For Common Margin % | 4.08 | 4.84 | 5.73 | 9.91 | 10.06 | |||||
Normalized Net Income Margin | 2.57 | 2.44 | 3.28 | 7.47 | 6.45 | |||||
Levered Free Cash Flow Margin | 4.46 | 12.61 | 14.88 | 15.35 | 9.33 | |||||
Unlevered Free Cash Flow Margin | 4.95 | 13.12 | 15.18 | 15.56 | 9.36 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.75 | 0.67 | 0.62 | 0.56 | 0.48 | |||||
Fixed Assets Turnover | 2.16 | 2.03 | 1.99 | 1.91 | 1.72 | |||||
Receivables Turnover (Average Receivables) | 4.87 | 4.49 | 5.01 | 6.31 | 7.29 | |||||
Inventory Turnover (Average Inventory) | 2.49 | 2.94 | 3.19 | 3.04 | 3.25 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.59 | 2.78 | 2.82 | 2.69 | 3.59 | |||||
Quick Ratio | 1.09 | 2.12 | 2.15 | 2.09 | 2.65 | |||||
Operating Cash Flow to Current Liabilities | 0.25 | 0.68 | 0.46 | 0.52 | 0.54 | |||||
Days Sales Outstanding (Average Receivables) | 74.96 | 81.25 | 72.87 | 57.97 | 50.04 | |||||
Days Outstanding Inventory (Average Inventory) | 146.61 | 124.33 | 114.28 | 120.43 | 112.21 | |||||
Average Days Payable Outstanding | 86.43 | 68.31 | 64.89 | 67.15 | 83.97 | |||||
Cash Conversion Cycle (Average Days) | 135.13 | 137.28 | 122.27 | 111.25 | 78.29 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 40.35 | 28 | 7.98 | 7.43 | 0.27 | |||||
Total Debt / Total Capital | 28.75 | 21.88 | 7.39 | 6.91 | 0.27 | |||||
LT Debt/Equity | 15.33 | 24.88 | 7.59 | 0.31 | 0.21 | |||||
Long-Term Debt / Total Capital | 10.93 | 19.44 | 7.03 | 0.29 | 0.21 | |||||
Total Liabilities / Total Assets | 45.62 | 38.09 | 25.91 | 23.22 | 17.59 | |||||
EBIT / Interest Expense | 9.76 | 7.84 | 16.71 | 42.09 | 253.96 | |||||
EBITDA / Interest Expense | 17.14 | 15.64 | 30.76 | 62.86 | 415.88 | |||||
(EBITDA - Capex) / Interest Expense | 12.42 | 12.77 | 24.58 | 56.9 | 355.72 | |||||
Total Debt / EBITDA | 2.21 | 2.03 | 0.64 | 0.49 | 0.02 | |||||
Net Debt / EBITDA | -0.05 | -1.64 | -2.71 | -2.81 | -3.85 | |||||
Total Debt / (EBITDA - Capex) | 3.05 | 2.48 | 0.8 | 0.54 | 0.03 | |||||
Net Debt / (EBITDA - Capex) | -0.07 | -2 | -3.39 | -3.1 | -4.5 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.06 | -7.07 | -6.86 | -9.38 | -14.4 | |||||
Gross Profit, 1 Yr. Growth % | 4.23 | -19.34 | -6.9 | -9.19 | -28.92 | |||||
EBITDA, 1 Yr. Growth % | 1.64 | -10.3 | 5.66 | 27.87 | -22.04 | |||||
EBITA, 1 Yr. Growth % | -1.63 | -21.48 | 13.54 | 55.85 | -26.49 | |||||
EBIT, 1 Yr. Growth % | -1.54 | -21.96 | 14.99 | 57.87 | -28.26 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -8.77 | 5.64 | 11.2 | 38.1 | -14.26 | |||||
Net Income, 1 Yr. Growth % | -12.41 | 10.47 | 10.21 | 56.62 | -13.11 | |||||
Normalized Net Income, 1 Yr. Growth % | 7.67 | -11.72 | 25.23 | 101.2 | -26.14 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -12.29 | 12.52 | 0.07 | 48.72 | -13.11 | |||||
Accounts Receivable, 1 Yr. Growth % | 17.11 | -12.86 | -22.77 | -33.64 | -14.27 | |||||
Inventory, 1 Yr. Growth % | -6.36 | -20.59 | -6.53 | -3.14 | -20.8 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.59 | -4.06 | -5.79 | -5.68 | -3.76 | |||||
Total Assets, 1 Yr. Growth % | 4.49 | 2.94 | -1.42 | 3.12 | -3.65 | |||||
Tangible Book Value, 1 Yr. Growth % | 7.78 | 22.13 | 21.69 | 6.28 | 3.26 | |||||
Common Equity, 1 Yr. Growth % | 5.68 | 19.93 | 20.21 | 6.58 | 4.35 | |||||
Cash From Operations, 1 Yr. Growth % | 7.66 | 70.01 | -39.76 | 31.13 | -24.73 | |||||
Capital Expenditures, 1 Yr. Growth % | 37.96 | -41.04 | 16.18 | -38.47 | 20.04 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -744.08 | 162.68 | 9.96 | -7.06 | -47.96 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -3.67K | 146.14 | 7.75 | -7.63 | -48.5 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 0 | 200 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.92 | 1.59 | -6.97 | -8.13 | -11.92 | |||||
Gross Profit, 2 Yr. CAGR % | 0.63 | -8.31 | -13.35 | -8.05 | -19.66 | |||||
EBITDA, 2 Yr. CAGR % | -0.25 | -4.38 | -2.47 | 17.43 | 0.28 | |||||
EBITA, 2 Yr. CAGR % | -3.03 | -11.9 | -5.26 | 34.48 | 7.24 | |||||
EBIT, 2 Yr. CAGR % | -2.68 | -12.35 | -5.27 | 35.85 | 6.42 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -5.96 | -1.83 | 8.38 | 23.92 | 8.81 | |||||
Net Income, 2 Yr. CAGR % | -6.95 | -1.63 | 10.34 | 31.38 | 16.66 | |||||
Normalized Net Income, 2 Yr. CAGR % | -0.27 | -2.51 | 5.14 | 60.73 | 21.91 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -8 | -0.66 | 6.11 | 22 | 13.68 | |||||
Accounts Receivable, 2 Yr. CAGR % | 31.45 | 1.02 | -17.97 | -28.41 | -24.57 | |||||
Inventory, 2 Yr. CAGR % | 15.12 | -13.77 | -13.85 | -4.85 | -12.41 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 2.08 | -1.28 | -4.93 | -5.74 | -4.73 | |||||
Total Assets, 2 Yr. CAGR % | 3.98 | 3.71 | 0.74 | 0.82 | -0.32 | |||||
Tangible Book Value, 2 Yr. CAGR % | 8.34 | 14.73 | 21.91 | 13.72 | 4.76 | |||||
Common Equity, 2 Yr. CAGR % | 6.42 | 12.58 | 20.07 | 13.19 | 5.46 | |||||
Cash From Operations, 2 Yr. CAGR % | 15 | 35.29 | 1.2 | -11.12 | -0.65 | |||||
Capital Expenditures, 2 Yr. CAGR % | 13.63 | -9.81 | -17.23 | -15.45 | -14.06 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 36.91 | 311.32 | 69.95 | 1.37 | -30.45 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 79.94 | 837.3 | 62.85 | 0.03 | -31.03 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 0 | 73.21 | 73.21 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 7.2 | 2.04 | -1.31 | -7.78 | -10.27 | |||||
Gross Profit, 3 Yr. CAGR % | 3.42 | -6.52 | -7.84 | -11.98 | -15.61 | |||||
EBITDA, 3 Yr. CAGR % | 2.26 | -3.63 | -1.03 | 7.47 | 2.74 | |||||
EBITA, 3 Yr. CAGR % | 2.33 | -9.48 | -3.91 | 12.65 | 10.1 | |||||
EBIT, 3 Yr. CAGR % | 2.56 | -9.58 | -4.05 | 12.93 | 9.81 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -8.45 | -2.24 | 2.34 | 17.5 | 9.6 | |||||
Net Income, 3 Yr. CAGR % | -6.96 | -1.47 | 2.17 | 24 | 14.47 | |||||
Normalized Net Income, 3 Yr. CAGR % | -5.85 | -4.24 | 5.98 | 31.63 | 24.03 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -9.27 | -1.61 | -0.41 | 18.75 | 8.95 | |||||
Accounts Receivable, 3 Yr. CAGR % | 20.76 | 14.62 | -7.63 | -23.56 | -23.98 | |||||
Inventory, 3 Yr. CAGR % | 9.89 | 1.72 | -11.42 | -10.42 | -10.49 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 2.2 | -0.01 | -2.8 | -5.18 | -5.08 | |||||
Total Assets, 3 Yr. CAGR % | 5.02 | 3.63 | 1.97 | 1.52 | -0.69 | |||||
Tangible Book Value, 3 Yr. CAGR % | 10.14 | 12.75 | 17.01 | 16.46 | 10.12 | |||||
Common Equity, 3 Yr. CAGR % | 8.08 | 10.74 | 15.07 | 15.4 | 10.17 | |||||
Cash From Operations, 3 Yr. CAGR % | 0.21 | 31 | 3.31 | 10.33 | -15.91 | |||||
Capital Expenditures, 3 Yr. CAGR % | 9.29 | -8.69 | -1.87 | -25.02 | -4.97 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -38.55 | 70.12 | 164.97 | 39.24 | -18.83 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -37.33 | 99.75 | 355.75 | 35.05 | -19.83 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | 0 | 44.22 | 44.22 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 8.85 | 8.76 | 1.29 | -2.16 | -5.7 | |||||
Gross Profit, 5 Yr. CAGR % | 13.44 | 6.06 | -3.64 | -7.14 | -12.76 | |||||
EBITDA, 5 Yr. CAGR % | -0.43 | -2.42 | 0.4 | 4.37 | -0.1 | |||||
EBITA, 5 Yr. CAGR % | -2.06 | -4.88 | -0.68 | 6.2 | 0.84 | |||||
EBIT, 5 Yr. CAGR % | -1.58 | -4.66 | -0.65 | 6.41 | 0.34 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -0.78 | 1.17 | -2.05 | 7.49 | 4.88 | |||||
Net Income, 5 Yr. CAGR % | 3.57 | 4.01 | -0.39 | 10.55 | 7.73 | |||||
Normalized Net Income, 5 Yr. CAGR % | 11.13 | 7.92 | -1.6 | 17.8 | 12.65 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 2.34 | 3.16 | -3.41 | 7.23 | 5 | |||||
Accounts Receivable, 5 Yr. CAGR % | 5 | 5.87 | 3.45 | -5.05 | -14.82 | |||||
Inventory, 5 Yr. CAGR % | 11.17 | 4.92 | -0.3 | -0.96 | -11.82 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -2.12 | -1.52 | -0.71 | -2.34 | -3.58 | |||||
Total Assets, 5 Yr. CAGR % | 4.9 | 5.29 | 3.29 | 2.5 | 1.05 | |||||
Tangible Book Value, 5 Yr. CAGR % | 11.38 | 13.44 | 14.7 | 13.14 | 11.94 | |||||
Common Equity, 5 Yr. CAGR % | 8.54 | 10.79 | 12.73 | 11.72 | 11.12 | |||||
Cash From Operations, 5 Yr. CAGR % | 14.9 | 4.29 | 0.61 | 12.18 | 1.71 | |||||
Capital Expenditures, 5 Yr. CAGR % | 16.66 | 12.79 | -2.21 | -11.46 | -6.94 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -2.21 | 4.19 | -7.69 | 38.3 | 55.35 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -4.67 | 2.69 | -8.18 | 51.48 | 114.37 | |||||
Dividend Per Share, 5 Yr. CAGR % | -5.11 | 14.87 | 0 | 24.57 | 24.57 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















